Cosmo Pharmaceuticals N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COPN.SW research report →
Price Chart
About the company
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
- CEO
- Giovanni di Napoli
- IPO
- 2007
- Employees
- 325
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on COPN.SW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.01B
- P/E
- -163.84
- Fwd P/E
- 487.10
- PEG
- 1.60
- P/S
- 10.42
- P/B
- 1.87
- EV/EBITDA
- -1639.04
- Div Yield
- 3.35%
- Gross Margin
- 45.52%
- Op Margin
- -13.37%
- Net Margin
- -6.18%
- ROE
- -1.21%
- ROIC
- -2.04%
Latest fiscal year · YoY change
- Revenue
- $104.85M-60.7%
- Gross Profit
- $48.78M-80.2%
- Op Income
- $-10,483,037
- Net Income
- $-3,631,568-102.7%
- EPS
- $-0.23-102.8%
- OCF Growth
- -107.2%
- FCF Growth
- -110.1%
- 52W High
- $129.40
- 52W Low
- $55.20
- 50D MA
- $64.23
- 200D MA
- $85.08
- Beta
- 1.59
- RSI (14)
- 32
- Avg Volume
- 31.07K
No earnings-call transcripts are available for COPN.SW yet.
- Free Float
- 50.2%
- Shares Outstanding
- 17.19M
- Float Shares
- 8.63M
Held by 132 ETFs
Biggest fund positions in COPN.SW by dollar value.
Our COPN.SW coverage
Recent articles, reports, and earnings notes.
No research on COPN.SW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COPN.SW report →Cosmo Announces SIX Ticker Symbol Change to "CMHC"
feeds.newsfilecorp.com · Aug 14
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
feeds.newsfilecorp.com · Jul 23
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
feeds.newsfilecorp.com · Jul 1
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
feeds.newsfilecorp.com · Jun 11
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
feeds.newsfilecorp.com · May 18
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
feeds.newsfilecorp.com · Apr 15
Voting Results of Cosmo's 2026 AGM
feeds.newsfilecorp.com · Apr 10
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
feeds.newsfilecorp.com · Mar 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.